Bank of America Cuts WAVE Life Sciences (NASDAQ:WVE) Price Target to $21.00

WAVE Life Sciences (NASDAQ:WVE) had its price target reduced by Bank of America from $38.00 to $21.00 in a research note released on Friday,Benzinga reports. They currently have a buy rating on the stock.

Other analysts have also recently issued reports about the company. Cantor Fitzgerald increased their price objective on WAVE Life Sciences from $34.00 to $41.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. Wedbush boosted their target price on WAVE Life Sciences from $33.00 to $35.00 and gave the company an “outperform” rating in a report on Friday, March 6th. B. Riley Financial upped their price target on WAVE Life Sciences from $19.00 to $37.00 and gave the stock a “buy” rating in a research note on Friday, December 12th. Royal Bank Of Canada raised WAVE Life Sciences from a “sector perform” rating to an “outperform” rating and increased their price target for the stock from $9.00 to $27.00 in a report on Monday, December 8th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of WAVE Life Sciences in a research report on Wednesday, January 21st. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $31.38.

WAVE Life Sciences Stock Performance

Shares of NASDAQ WVE opened at $6.36 on Friday. WAVE Life Sciences has a fifty-two week low of $5.02 and a fifty-two week high of $21.73. The firm has a market capitalization of $1.20 billion, a PE ratio of -5.21 and a beta of -1.77. The stock’s 50-day simple moving average is $12.93 and its 200-day simple moving average is $11.25.

WAVE Life Sciences (NASDAQ:WVE) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.02). WAVE Life Sciences had a negative net margin of 478.35% and a negative return on equity of 85.69%. The company had revenue of $17.25 million during the quarter, compared to analysts’ expectations of $15.68 million. On average, sell-side analysts forecast that WAVE Life Sciences will post -1.14 earnings per share for the current fiscal year.

Insider Activity at WAVE Life Sciences

In related news, insider Chris Francis sold 33,194 shares of the firm’s stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $15.05, for a total value of $499,569.70. Following the completion of the transaction, the insider directly owned 61,867 shares of the company’s stock, valued at $931,098.35. This trade represents a 34.92% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Paul Bolno sold 10,480 shares of the firm’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $13.45, for a total value of $140,956.00. Following the completion of the transaction, the chief executive officer owned 275,520 shares of the company’s stock, valued at approximately $3,705,744. This represents a 3.66% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 61,748 shares of company stock valued at $907,809. 23.98% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Voya Investment Management LLC increased its position in WAVE Life Sciences by 736.5% during the third quarter. Voya Investment Management LLC now owns 258,011 shares of the company’s stock worth $1,889,000 after buying an additional 227,167 shares in the last quarter. Handelsbanken Fonder AB purchased a new stake in shares of WAVE Life Sciences in the second quarter valued at $330,000. JPMorgan Chase & Co. boosted its stake in shares of WAVE Life Sciences by 33.1% during the second quarter. JPMorgan Chase & Co. now owns 1,569,015 shares of the company’s stock valued at $10,199,000 after acquiring an additional 390,078 shares during the last quarter. Federated Hermes Inc. boosted its stake in shares of WAVE Life Sciences by 678,144.7% during the third quarter. Federated Hermes Inc. now owns 3,750,693 shares of the company’s stock valued at $27,455,000 after acquiring an additional 3,750,140 shares during the last quarter. Finally, Schroder Investment Management Group increased its position in WAVE Life Sciences by 29.7% during the 2nd quarter. Schroder Investment Management Group now owns 621,378 shares of the company’s stock worth $4,039,000 after purchasing an additional 142,109 shares in the last quarter. 89.73% of the stock is currently owned by institutional investors and hedge funds.

WAVE Life Sciences News Roundup

Here are the key news stories impacting WAVE Life Sciences this week:

• Positive Sentiment: Company press release: management highlighted six‑month, placebo‑adjusted improvements in body composition (240 mg single dose produced ~14% visceral fat reduction, ~5% total fat reduction, +2% lean mass, ~3.3% waist circumference reduction) and continued safety/tolerability — data that supports the therapy’s mechanism and future development plans. Wave press release
• Positive Sentiment: Management commentary / transcripts emphasize the visceral‑fat and body‑composition signal and durability at six months, which supporters point to as a differentiated outcome versus pure body‑weight endpoints. Seeking Alpha transcript
• Positive Sentiment: Analyst positioning remains mixed but includes continued conviction from some firms: Bank of America kept a Buy rating (PT cut), Wells Fargo kept Overweight (PT cut), Truist upgraded to Strong‑Buy and Mizuho issued bullish commentary — these voices can limit downside and attract buyers after the sell‑off. Benzinga (analyst notes)
• Neutral Sentiment: Independent outlets and investor notes characterize the data as “clinically interesting” on body composition but still early‑stage and not yet persuasive on meaningful weight loss — meaning future development and larger trials will determine value. ProactiveInvestors report
• Negative Sentiment: Market reaction: shares plunged >50% after investors focused on the modest ~0.9% body‑weight reduction at six months and the higher‑dose readout that “failed to show a clear improvement” by some measures — the gap between body‑composition signals and headline weight loss disappointed traders. Reuters
• Negative Sentiment: Investor/legal risk: a law firm is publicizing an investigation into potential claims by shareholders, adding litigation overhang and downward pressure on sentiment. GlobeNewswire (Johnson Fistel)
• Negative Sentiment: Analyst downgrades and target cuts followed the update; multiple outlets report steep target cuts and downgrades that reflect lower near‑term expectations and have likely amplified selling pressure. Seeking Alpha downgrade

WAVE Life Sciences Company Profile

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.